Moleculin Biotech, Inc. — Director's Dealing 2023

Jun 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2023-06-22

Reporting Person: Foster Jonathan P. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-22	Stock option (right to buy)	$0.60	A	150000	Acquired	2033-06-22	Common Stock (150000)	Direct
2023-06-22	Restricted Stock Units	$	A	259688	Acquired		Common Stock (259688)	Direct

Footnotes

F1: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

F2: Issued in connection with the reporting person's employment with the Company.

F3: Each restricted stock unit represents a contingent right to receive one shares of Company common stock.

F4: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.